Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > So far so good

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 08, 2021 12:30pm

61 Views

Post# 32957190

RE:RE:RE:RE:RE:So far so good

You have to realize that your opinion does not fit with the facts of the trial design as stated on clinicaltrials.gov

jfm1330 wrote: I still think that they will give the drug to patients with histological confirmation of sortilin overwxpression. Look at this recent article on a study on the role of sortilin and progranulin overexpression in breast cancer. All the patients involved had biopsies with histological confirmation of overexpression. Thera should make it clear, instead of stuff like "all solid tumor". I believe in the potential of their PDC approach, Th1902 or other combination, but it could only work on properly selected patients with confirmed cancer with sortilin overexpression. I don't need a webcast, I just need them to make that clear in their written or oral presentations. Right now it's not clear and it is problematic. Maybe they think it is so obvious that they don't need to specify it, but the example of Dr. Shah shows it's not the case.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-07854-0

Wino115 wrote: I noticed that too. He listed most of the ones that THTX has also spoken about, but as we know some of those only have one third or so of patients where it overexpresses. Also, he made it seem like it was a first line approach. Maybe we'll get there, but we also know that the more severe the cancer metastices, the more sortilin is expressed so it may not be the case. It's more specialized than what he seemed to be saying in the TV segment.

jfm1330 wrote: Cannot believe they would select a patient without knowing his cancer has overexpression of sortilin. That being said, what Dr. Shah is saying, that it can be used on any solid tumor is scary, because it's not the case. The key of the whole thing is sortilin overexpression. Without that, it will not work as planned.

Wino115 wrote: This is the first time we've heard Prostate Cancer... I'm not sure what level of Sortilin is expressed for that. Or is that what they've put under the more generic "gynecological" cancers? Hope it works, but not the primary kind of tumor we're looking for.

scarlet1967 wrote: https://www.abc27.com/news/local/gettysburg-doctor-patient-first-in-the-world-to-try-new-cancer-treatment/amp/